NYSE: CRLCharles River Laboratories
Charles River Laboratories Q3 2026 Results: Net Income $333 Million on Revenue of $983 Million
- US stocks
- Earnings
- Health Care

Charles River Laboratories (NYSE: CRL) reported third-quarter 2026 results for the quarter ended 26 Sep 2026. GAAP revenue was $982.7 million and GAAP net income attributable to common shareholders was $333.1 million, it said on 4 Nov 2026. GAAP diluted EPS was $6.86, and adjusted EPS, a company-defined non-GAAP measure, was $3.09.
Key highlights
- Revenue (GAAP): $982.7 million, down 2.2% YoY and 2.1% QoQ
- Net income (GAAP, attributable to common shareholders): $333.1 million, up 512.0% YoY
- Diluted EPS (GAAP): $6.86, up 523.6% YoY
- Adjusted EPS (company-defined, non-GAAP): $3.09, up 27.2% YoY
- Operating margin (GAAP): 20.6%, up 7.3 percentage points YoY
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 982.7 | 1,004.9 | -2.2% | 1,004.1 | -2.1% |
| 202.6 | 133.8 | +51.4% | 119.9 | +69.0% | |
| Operating margin | 20.62% | 13.32% | +7.30 pp | 11.94% | +8.68 pp |
| 333.1 | 54.4 | +512.0% | -1.5 | n/a | |
| Net income margin | 33.89% | 5.42% | +28.47 pp | -0.15% | +34.04 pp |
| Diluted EPS ($) | 6.86 | 1.10 | +523.6% | -0.03 | n/a |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 26 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table compares the quarter with the same quarter of 2025 and with the previous quarter. Operating income of $202.6 million was up 51.4% from a year earlier and up 69.0% from the previous quarter, and the GAAP operating margin of 20.6% compared with 13.3% a year earlier. The previous quarter had a GAAP net loss of $1.5 million, so no percentage change is shown for net income against it.
Adjusted figures exclude the tax reserve reversal
The company's non-GAAP measures, which it says exclude items such as acquisition and divestiture costs, amortization of acquired intangibles, restructuring costs and investment gains and losses, show non-GAAP net income of $150.1 million, up 24.8% from $120.3 million. The non-GAAP operating margin was 23.0%, against 19.7% a year earlier. The company said GAAP net income and EPS included a $245.6 million benefit, or $5.06 per share, from the reversal of acquired tax reserves, and its reconciliation removes that reversal from the non-GAAP figures.
Organic growth came from Manufacturing and DSA
The company said organic revenue growth of 4.7% came from the Manufacturing Solutions and DSA segments. DSA revenue was $596.3 million, down 0.7% as reported and up 5.9% organically. Its GAAP operating margin rose to 28.9% from 20.5%, which the company attributed mainly to the reversal of acquired non-income tax reserves, while its non-GAAP margin was 26.8%.
Manufacturing Solutions revenue was $178.9 million, down 6.2% as reported and up 7.4% organically. Its GAAP operating margin rose to 35.7% from 20.9%, a rise the company attributed to the CDMO divestiture. Research Models and Services revenue was $207.5 million, down 2.8%, and organic revenue fell 0.6%. Its non-GAAP operating margin fell to 24.4% from 25.0%, which the company attributed to an unfavorable revenue mix.
Outlook raised for 2026
The company now expects 2026 GAAP EPS of $8.15 to $8.35, up from $3.05 to $3.35, and non-GAAP EPS of $11.35 to $11.55, up from $11.15 to $11.45. Reported revenue growth is now (2.0)% to (1.5)%, from (3.5)% to (2.5)%, and organic growth is at least 1.5%, from 0.0% to 1.0%. The company said the increase primarily reflects third-quarter outperformance and a lower tax rate, and that the GAAP EPS increase is due mainly to the tax reserve reversal.
Inference
Diluted weighted-average shares were 48,584 thousand in the quarter, against 49,426 thousand a year earlier. In the nine months to 26 Sep 2026, the company bought back treasury stock for $324.1 million. The release does not state a dividend, or any quarter-only cash flow or buyback amount.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.
